nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.06.2015

Allosteric therapies for lung cancer

verfasst von: Ye Ling, Meiling Jing, Xiang-dong Wang

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Allostery is a regulation at a distance by conveying information from one site to another and an intrinsic property of dynamic proteins. Allostery plays an essential role in receptor trafficking, signal transmission, controlled catalysis, gene turn on/off, or cell apoptosis. Allosteric mutations are considered as one of causes responsible for cancer development, leading to “allosteric diseases” by stabilizing an active or inactive conformation or changing the dynamic distribution of preexisting propagation pathways. The present article mainly focuses on the potential of allosteric therapies for lung cancer. Allosteric drugs may have several advantages over traditional drugs. The epidermal growth factor receptor mutations and signaling pathways downstream (such as PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways) were suggested to play a key role in lung cancer and considered as targets of allosteric therapy. Some allosteric inhibitors for lung cancer-specific targets and a series of preclinical trials of allosteric inhibitors for lung cancer have been developed and reported. We expect that allosteric therapies will gain more attentions to develop combinatorial strategies for lung cancer and metastasis.

Di Paola, L., & Giuliani, A. (2015). Protein contact network topology: a natural language for allostery. Current Opinion in Structural Biology, 31, 43–48.PubMedCrossRef

Nussinov, R., & Tsai, C. J. (2013). Allostery in disease and in drug discovery. Cell, 153(2), 293–305.PubMedCrossRef

Tsai, C. J., Del Sol, A., & Nussinov, R. (2009). Protein allostery, signal trans- mission and dynamics: a classification scheme of allosteric mechanisms. Molecular Biosystems, 5(3), 207–216.PubMedCentralPubMedCrossRef

Changeux, J. P. (2012). Allostery and the Monod-Wyman-Changeux model after 50 years. Annual Review of Biophysics, 41, 103–133.PubMedCrossRef

Collier, G., & Ortiz, V. (2013). Emerging computational approaches for the study of protein allostery. Archives Biochemistry and Biophysics, 538(1), 6–15.CrossRef

Manley, G., & Loria, J. P. (2012). NMR insights into protein allostery. Archives Biochemistry and Biophysics, 519(2), 223–231.CrossRef

Fenwick, R. B., Esteban-Martín, S., & Salvatella, X. (2014). The ensemble nature of allostery. Nature, 508(7496), 331–339.CrossRef

Strickland, D., Moffat, K., & Sosnick, T. R. (2008). Light-activated DNA binding in a designed allosteric protein. Proceedings of the National Academy of Sciences of the United States of America, 105(31), 10709–10714.PubMedCentralPubMedCrossRef

Csermely, P., Palotai, R., & Nussinov, R. (2010). Induced fit, conformational selection and independent dynamic segments: an extended view of binding events. Trends in Biochemical Sciences, 35(10), 539–546.PubMedCentralPubMedCrossRef

10.

Mittag, T., Kay, L. E., & Forman-Kay, J. D. (2010). Protein dynamics and conformational disorder in molecular recognition. Journal of Molecular Recognition, 23(2), 105–116.PubMed

11.

Nussinov, R., Tsai, C. J., Xin, F., & Radivojac, P. (2012). Allosteric post-translational modification codes. Trends in Biochemical Sciences, 37(10), 447–455.PubMedCrossRef

12.

Ma, B., Tsai, C. J., Haliloğlu, T., & Nussinov, R. (2011). Dynamic allostery: linkers are not merely flexible. Structure, 19(7), 907–917.PubMedCrossRef

13.

del Sol, A., Tsai, C. J., Ma, B., & Nussinov, R. (2009). The origin of allosteric functional modulation: multiple pre-existing pathways. Structure, 17(8), 1042–1050.PubMedCentralPubMedCrossRef

14.

Tsai, C. J., del Sol, A., & Nussinov, R. (2008). Allostery: absence of a change in shape does not imply that allostery is not at play. Journal of Molecular Biology, 378(1), 1–11.PubMedCentralPubMedCrossRef

15.

Boehr, D. D., Nussinov, R., & Wright, P. E. (2009). The role of dynamic conformational ensembles in biomolecular recognition. Nature Chemical Biology, 5(11), 789–796.PubMedCentralPubMedCrossRef

16.

Kar, G., Keskin, O., Gursoy, A., & Nussinov, R. (2010). Allostery and population shift in drug discovery. Current Opinion in Pharmacology, 10(6), 715–722.PubMedCrossRef

17.

Popovych, N., Sun, S., Ebright, R. H., & Kalodimos, C. G. (2006). Dynamically driven protein allostery. Nature Structural & Molecular Biology, 13(9), 831–838.CrossRef

18.

Urwyler, S. (2011). Allosteric modulation of family C G-protein-coupled receptors: from molecular insights to therapeutic perspectives. Pharmacological Reviews, 63(1), 59–126.PubMedCrossRef

19.

De Lean, A., Stadel, J. M., & Lefkowitz, R. J. (1980). A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta- adrenergic receptor. Journal of Biological Chemistry, 255(15), 7108–7117.PubMed

20.

Keov, P., Sexton, P. M., & Christopoulos, A. (2011). Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology, 60(1), 24–35.PubMedCrossRef

21.

Leach, K., Loiacono, R. E., Felder, C. C., McKinzie, D. L., Mogg, A., Shaw, D. B., Sexton, P. M., & Christopoulos, A. (2010). Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology, 35(4), 855–869.PubMedCentralPubMedCrossRef

22.

Suratman, S., Leach, K., Sexton, P., Felder, C., Loiacono, R., & Christopoulos, A. (2011). Impact of species variability and ‘probe-dependence’ on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. British Journal of Pharmacology, 162(7), 1659–1670.PubMedCentralPubMedCrossRef

23.

Valant, C., Felder, C. C., Sexton, P. M., & Christopoulos, A. (2012). Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects. Molecular Pharmacology, 81(1), 41–52.PubMedCrossRef

24.

Gregory, K. J., Dong, E. N., Meiler, J., & Conn, P. J. (2011). Allosteric modulation of metabotropic glutamate receptors: structural insights and therapeutic potential. Neuropharmacology, 60(1), 66–81.PubMedCentralPubMedCrossRef

25.

Hall, D. A. (2000). Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Molecular Pharmacology, 58(6), 1412–1423.PubMed

26.

Christopoulos, A., & Kenakin, T. (2002). G protein-coupled receptor allosterism and complexing. Pharmacological Reviews, 54(2), 323–374.PubMedCrossRef

27.

Nussinov, R., Tsai, C. J., & Ma, B. (2013). The underappreciated role of allostery in the cellular network. Annual Review of Biophysics, 42, 169–189.PubMedCrossRef

28.

Tzeng, S. R., & Kalodimos, C. G. (2011). Protein dynamics and allostery: an NMR view. Current Opinion in Structural Biology, 21(1), 62–67.PubMedCrossRef

29.

Popovych, N., Tzeng, S. R., Tonelli, M., Ebright, R. H., & Kalodimos, C. G. (2009). Structural basis for cAMP-mediated allosteric control of the catabolite activator protein. Proceedings of the National Academy of Sciences of the United States of America, 106(17), 6927–6932.PubMedCentralPubMedCrossRef

30.

Tzeng, S. R., & Kalodimos, C. G. (2009). Dynamic activation of an allosteric regulatory protein. Nature, 462(7271), 368–372.PubMedCrossRef

31.

Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., & Evers, B. M. (2012). mTOR inhibitors in cancer therapy. Cancer Letters, 319(1), 1–7.PubMedCrossRef

32.

Goncharova, E. A. (2013). mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects. FASEB Journal, 27(5), 1796–1807.PubMedCentralPubMedCrossRef

33.

Geserick, C., Meyer, H. A., & Haendler, B. (2005). The role of DNA response elements as allosteric modulators of steroid receptor function. Molecular and Cellular Endocrinology, 236(1-2), 1–7.PubMedCrossRef

34.

Ma, B., Tsai, C. J., Pan, Y., & Nussinov, R. (2010). Why does binding of proteins to DNA or proteins to proteins not necessarily spell function? ACS Chemical Biology, 5(3), 265–272.PubMedCentralPubMedCrossRef

35.

Garcia, H. G., Sanchez, A., Boedicker, J. Q., Osborne, M., Gelles, J., Kondev, J., & Phillips, R. (2012). Operator sequence alters gene expression independently of transcription factor occupancy in bacteria. Cell Reports, 2(1), 150–161.PubMedCentralPubMedCrossRef

36.

Kim, S., Broströmer, E., Xing, D., Jin, J., Chong, S., Ge, H., Wang, S., Gu, C., Yang, L., Gao, Y. Q., Su, X. D., Sun, Y., & Xie, X. S. (2013). Probing allostery through DNA. Science, 339(6121), 816–819.PubMedCentralPubMedCrossRef

37.

Wootten, D., Christopoulos, A., & Sexton, P. M. (2013). Emerging paradigms in GPCR allostery: implications for drug discovery. Nature Reviews Drug Discovery, 12(8), 630–644.PubMedCrossRef

38.

Schelshorn, D., Joly, F., Mutel, S., Hampe, C., Breton, B., Mutel, V., & Lütjens, R. (2012). Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation. Molecular Pharmacology, 81(3), 309–318.PubMedCrossRef

39.

Foster, A. C., & Kemp, J. A. (2006). Glutamate- and GABA-based CNS therapeutics. Current Opinion in Pharmacology, 6(1), 7–17.PubMedCrossRef

40.

Lindberg, J. S., Culleton, B., Wong, G., Borah, M. F., Clark, R. V., Shapiro, W. B., Roger, S. D., Husserl, F. E., Klassen, P. S., Guo, M. D., Albizem, M. B., & Coburn, J. W. (2005). Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Journal of the American Society of Nephrology, 16(3), 800–807.PubMedCrossRef

41.

Lieberman-Blum, S. S., Fung, H. B., & Bandres, J. C. (2008). Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clinical Therapeutics, 30(7), 1228–1250.PubMedCrossRef

42.

Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011). Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. Journal of Clinical Investigation, 121(4), 1231–1241.PubMedCentralPubMedCrossRef

43.

Lu, S., Li, S., & Zhang, J. (2014). Harnessing allostery: a novel approach to drug discovery. Medicinal Research Reviews, 34(6), 1242–1285.PubMedCrossRef

44.

Alamgeer, M., Ganju, V., & Watkins, D. N. (2013). Novel therapeutic targets in non-small cell lung cancer. Current Opinion in Pharmacology, 13(3), 394–401.PubMedCrossRef

45.

Li, T., Kung, H. J., Mack, P. C., & Gandara, D. R. (2013). Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. Journal of Clinical Oncology, 31(8), 1039–1049.PubMedCentralPubMedCrossRef

46.

Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J. S., Squire, J., Thunnissen, E., & Ladanyi, M. (2013). Molecular testing guideline for Selection of Lung Cancer Patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Molecular Diagnostics, 15(4), 415–453.PubMedCrossRef

47.

Hynes, N. E., & MacDonald, G. (2009). ErbB receptors and signaling pathways in cancer. Current Opinion in Cell Biology, 21(2), 177–184.PubMedCrossRef

48.

Endres, N. F., Engel, K., Das, R., Kovacs, E., & Kuriyan, J. (2011). Regulation of the catalytic activity of the EGF receptor. Current Opinion in Structural Biology, 21(6), 777–784.PubMedCentralPubMedCrossRef

49.

Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell, 125(6), 1137–1149.PubMedCrossRef

50.

Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., & Kuriyan, J. (2011). Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Molecular Cell, 42(1), 9–22.PubMedCentralPubMedCrossRef

51.

Jura, N., Endres, N. F., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2009). Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell, 137(7), 1293–1307.PubMedCentralPubMedCrossRef

52.

Papakyriakou, A., Vourloumis, D., Tzortzatou-Stathopoulou, F., & Karpusas, M. (2009). Conformational dynamics of the EGFR kinase domain reveals structural features involved in activation. Proteins, 76(2), 375–386.PubMedCrossRef

53.

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, 350(21), 2129–2139.PubMedCrossRef

54.

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E., & Meyerson, M. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304(5676), 1497–1500.PubMedCrossRef

55.

Gazdar, A. F. (2009). Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene, 28(S1), S24–S31.PubMedCentralPubMedCrossRef

56.

Yun, C. H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007). Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell, 11(3), 217–227.PubMedCentralPubMedCrossRef

57.

Shan, Y., Eastwood, M. P., Zhang, X., Kim, E. T., Arkhipov, A., Dror, R. O., Jumper, J., Kuriyan, J., & Shaw, D. E. (2012). Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell, 149(4), 860–870.PubMedCrossRef

58.

Dixit, A., & Verkhivker, G. M. (2011). Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases. PLoS Computational Biology, 7(10), e1002179.PubMedCentralPubMedCrossRef

59.

Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clinical Cancer Research, 12(19), 5764–5769.PubMedCrossRef

60.

Yun, C. H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. K., Meyerson, M., & Eck, M. J. (2008). The T790 mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America, 105(6), 2070–2075.PubMedCentralPubMedCrossRef

61.

Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., & Daley, G. Q. (2008). Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nature Structural & Molecular Biology, 15(10), 1109–1118.CrossRef

62.

Santarpia, L., Lippman, S. M., & El-Naggar, A. K. (2012). Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 16(1), 103–119.PubMedCentralPubMedCrossRef

63.

Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews Drug Discovery, 8(8), 627–644.PubMedCentralPubMedCrossRef

64.

Britten, C. D. (2013). PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemotherapy and Pharmacology, 71(6), 1395–1409.PubMedCrossRef

65.

Chappell, W. H., Steelman, L. S., Long, J. M., Kempf, R. C., Abrams, S. L., Franklin, R. A., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Malaponte, G., Mazzarino, M. C., Nicoletti, F., Libra, M., Maksimovic-Ivanic, D., Mijatovic, S., Montalto, G., Cervello, M., Laidler, P., Milella, M., Tafuri, A., Bonati, A., Evangelisti, C., Cocco, L., Martelli, A. M., & McCubrey, J. A. (2011). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget, 2(3), 135–164.PubMedCentralPubMed

66.

McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Montalto, G., Cervello, M., Nicoletti, F., Fagone, P., Malaponte, G., Mazzarino, M. C., Candido, S., Libra, M., Bäsecke, J., Mijatovic, S., Maksimovic-Ivanic, D., Milella, M., Tafuri, A., Cocco, L., Evangelisti, C., Chiarini, F., & Martelli, A. M. (2012). Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/ mTOR cascades which alter therapy response. Oncotarget, 3(9), 954–987.PubMedCentralPubMed

67.

McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Franklin, R. A., Montalto, G., Cervello, M., Libra, M., Candido, S., Malaponte, G., Mazzarino, M. C., Fagone, P., Nicoletti, F., Bäsecke, J., Mijatovic, S., Maksimovic-Ivanic, D., Milella, M., Tafuri, A., Chiarini, F., Evangelisti, C., Cocco, L., & Martelli, A. M. (2012). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget, 3(10), 1068–1111.PubMedCentralPubMed

68.

Iida, M., Brand, T. M., Campbell, D. A., Starr, M. M., Luthar, N., Traynor, A. M., & Wheeler, D. L. (2013). Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biology & Therapy, 14(6), 481–491.CrossRef

69.

Holland, W. S., Chinn, D. C., Lara, P. N., Jr., Gandara, D. R., & Mack, P. C. (2015). Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. Journal of Cancer Research and Clinical Oncology, 141(4), 615–626.PubMedCrossRef

70.

Gadgeel, S. M., & Wozniak, A. (2013). Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clinical Lung Cancer, 14(4), 322–332.PubMedCrossRef

71.

Soria, J. C., Shepherd, F. A., Douillard, J. Y., Wolf, J., Giaccone, G., Crino, L., Cappuzzo, F., Sharma, S., Gross, S. H., Dimitrijevic, S., Di Scala, L., Gardner, H., Nogova, L., & Papadimitrakopoulou, V. (2009). Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Annals of Oncology, 20(10), 1674–1681.PubMedCrossRef

72.

Price, K. A., Azzoli, C. G., Krug, L. M., Pietanza, M. C., Rizvi, N. A., Pao, W., Kris, M. G., Riely, G. J., Heelan, R. T., Arcila, M. E., & Miller, V. A. (2010). Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. Journal of Thoracic Oncology, 5(10), 1623–1629.PubMedCentralPubMedCrossRef

73.

Ramalingam, S. S., Owonikoko, T. K., Behera, M., Subramanian, J., Saba, N. F., Kono, S. A., Gal, A. A., Sica, G., Harvey, R. D., Chen, Z., Klass, C. M., Shin, D. M., Fu, H., Sun, S. Y., Govindan, R., & Khuri, F. R. (2013). Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. Journal of Thoracic Oncology, 8(3), 369–372.PubMedCentralPubMedCrossRef

74.

Besse, B., Leighl, N., Bennouna, J., Papadimitrakopoulou, V. A., Blais, N., Traynor, A. M., Soria, J. C., Gogov, S., Miller, N., Jehl, V., & Johnson, B. E. (2014). Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer. Annals of Oncology, 25(2), 409–415.PubMedCrossRef

75.

Hainsworth, J. D., Cebotaru, C. L., Kanarev, V., Ciuleanu, T. E., Damyanov, D., Stella, P., Ganchev, H., Pover, G., Morris, C., & Tzekova, V. (2010). A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. Journal of Thoracic Oncology, 5(10), 1630–1636.PubMedCrossRef

76.

Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., Smith, I., & Crinò, L. (2013). Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncology, 14(1), 38–47.PubMedCrossRef

77.

Infante, J. R., Papadopoulos, K. P., Bendell, J. C., Patnaik, A., Burris, H. A., Rasco, D., Jones, S. F., Smith, L., Cox, D. S., Durante, M., Bellew, K. M., Park, J. J., Le, N. T., & Tolcher, A. W. (2013). A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. European Journal of Cancer, 49(9), 2077–2085.PubMedCrossRef

78.

Blumenschein, G. R., Jr., Smit, E. F., Planchard, D., Kim, D. W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M. J., Hanna, N. H., Kim, J. H., Mazieres, J., Kim, S. W., Baas, P., Rappold, E., Redhu, S., Puski, A., Wu, F. S., & Jänne, P. A. (2015). A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. Annals of Oncology, 26(5), 894–901.PubMedCrossRef

79.

Zimmer, L., Barlesi, F., Martinez-Garcia, M., Dieras, V., Schellens, J. H., Spano, J. P., Middleton, M. R., Calvo, E., Paz-Ares, L., Larkin, J., Pacey, S., Venturi, M., Kraeber-Bodéré, F., Tessier, J. J., Eberhardt, W. E., Paques, M., Guarin, E., Meresse, V., & Soria, J. C. (2014). Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clinical Cancer Research, 20(16), 4251–4261.PubMedCrossRef

80.

Honda, K., Yamamoto, N., Nokihara, H., Tamura, Y., Asahina, H., Yamada, Y., Suzuki, S., Yamazaki, N., Ogita, Y., & Tamura, T. (2013). Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 72(3), 577–584.PubMedCrossRef

Titel: Allosteric therapies for lung cancer
verfasst von: Ye Ling
Meiling Jing
Xiang-dong Wang
Publikationsdatum: 01.06.2015
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 2/2015
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-015-9567-z

Springer Medizin

Allosteric therapies for lung cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2015

Radiation therapy for oligometastatic non-small cell lung cancer

Regulatory T cells and potential inmmunotherapeutic targets in lung cancer

Erratum to: Association of chromosome 19 to lung cancer genotypes and phenotypes

Relationship between gene mutation and lung cancer metastasis

Biographies

Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie